<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pediatric mania and second-generation antipsychotics: Efficacy, administration, and side effects
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pediatric mania and second-generation antipsychotics: Efficacy, administration, and side effects
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pediatric mania and second-generation antipsychotics: Efficacy, administration, and side effects
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Axelson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Brent, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H107239028">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children and adolescents with mania, second-generation antipsychotics are often efficacious and thus frequently prescribed. As an example, a nationally representative survey of outpatient visits for bipolar disorder in the United States between 2005 and 2009 found that in adolescents, antipsychotics were prescribed in 29 percent of the visits [
         <a href="#rid1">
          1
         </a>
         ]. In younger children, antipsychotics were prescribed in 12 percent of the visits.
        </p>
        <p>
         This topic reviews the efficacy, administration, and side effects of second-generation antipsychotics in youth with mania. Other aspects of pediatric bipolar disorder are discussed separately, including an overview of choosing treatment; general principles of using pharmacotherapy; the efficacy and core elements of adjunctive psychotherapy; assessment and diagnosis; and the epidemiology, clinical features, and course of illness:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15925.html" rel="external">
          "Pediatric bipolar disorder: Overview of choosing treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/98716.html" rel="external">
          "Pediatric bipolar disorder and pharmacotherapy: General principles"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/98754.html" rel="external">
          "Pediatric bipolar disorder: Efficacy and core elements of adjunctive psychotherapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/83083.html" rel="external">
          "Pediatric bipolar disorder: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15924.html" rel="external">
          "Pediatric bipolar disorder: Clinical manifestations and course of illness"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H107239035">
         <span class="h1">
          SPECIFIC DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized trials have demonstrated the efficacy of
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="117924" href="/z/d/drug information/117924.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         for children and adolescents with mania. No head-to-head trials have compared these drugs; nevertheless, there appear to be differences in some adverse effects.
        </p>
        <p class="headingAnchor" id="H107239042">
         <span class="h2">
          Aripiprazole
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence for the efficacy of
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         in treating pediatric mania, mixed mania, and subsyndromal manic symptoms includes three randomized trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A four-week trial (n = 296) that compared
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         (target dose either 10 mg/day or 30 mg/day) with placebo found that remission occurred in more patients who received aripiprazole 10 mg or 30 mg than placebo (25 and 48 versus 5 percent) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A six-week trial compared
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         (mean dose 14 mg/day) with placebo in manic patients with comorbid attention deficit hyperactivity disorder (ADHD) (n = 43) [
         <a href="#rid3">
          3
         </a>
         ]. Remission of mania occurred in more patients treated with aripiprazole than placebo (72 versus 32 percent). However, improvement of ADHD was comparable for the two groups, as was improvement of mixed (depressive) features.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 12-week trial compared
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         (mean dose 7 mg) with placebo in youth aged 5 to 17 years (n = 59), who were diagnosed with cyclothymic disorder or bipolar disorder not otherwise specified, and had a family history of bipolar disorder [
         <a href="#rid4">
          4
         </a>
         ]. Improvement of manic symptoms and functioning was greater with aripiprazole than placebo, and the clinical difference was large. However, emesis was greater with active drug, as was weight gain (2.3 versus 0.7 kg).
        </p>
        <p>
        </p>
        <p>
         In children and adolescents, oral
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         is routinely administered once daily at bedtime, and the starting dose frequently depends upon the child’s weight [
         <a href="#rid2">
          2,3
         </a>
         ]. Based upon one study, we suggest that patients weighing &lt;25 kg receive 1 mg/day at treatment onset, patients weighing 25 to 50 kg receive 2 mg/day, and those weighing &gt;50 kg start at 5 mg/day [
         <a href="#rid5">
          5
         </a>
         ]. The dose is then titrated up by 1 to 5 mg every two to seven days depending upon response and tolerability, to a target dose ranging from 5 to 30 mg/day.
        </p>
        <p>
         Common side effects include akathisia, sedation, nausea, vomiting, and weight gain [
         <a href="#rid6">
          6
         </a>
         ]. As an example, a randomized trial (n = 296) found that akathisia occurred in more patients treated with
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         10 mg/day and 30 mg/day than placebo (8 and 11 versus 2 percent), as did sedation (19 and 26 versus 3 percent) [
         <a href="#rid2">
          2,7
         </a>
         ]. In addition, mean weight gain over 30 weeks was greater with aripiprazole 10 mg/day and 30 mg/day than placebo (7 and 7 versus 3 kg) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3849425210">
         <span class="h2">
          Asenapine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence for the efficacy of
         <a class="drug drug_pediatric" data-topicid="117924" href="/z/d/drug information/117924.html" rel="external">
          asenapine
         </a>
         in treating pediatric mania or mixed mania includes a three-week randomized trial (n = 395) that compared asenapine at three different doses (2.5, 5, or 10 mg twice per day) with placebo [
         <a href="#rid9">
          9
         </a>
         ]. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received asenapine 2.5, 5, or 10 mg than placebo (42, 54, and 52 versus 28 percent). Discontinuation of treatment due to adverse effects was comparable for all doses of asenapine (5 to 7 percent of patients) and placebo (4 percent).
        </p>
        <p>
         Common side effects of
         <a class="drug drug_pediatric" data-topicid="117924" href="/z/d/drug information/117924.html" rel="external">
          asenapine
         </a>
         in the randomized trial included sedation, increased appetite, and oral hypo/paresthesia [
         <a href="#rid9">
          9
         </a>
         ]. (Asenapine is administered sublingually, and the oral hypo/paresthesia is due to local anesthetic effects.) In addition, weight gain ≥7 percent from baseline occurred in more patients treated with asenapine 2.5, 5, or 10 mg twice per day, compared with placebo (12, 9, and 8 versus 1 percent). Increases in fasting glucose, insulin, cholesterol, low density lipoprotein, and triglycerides were each greater with all asenapine doses than placebo; although the difference between asenapine and placebo for each of these metabolic factors was not statistically different in this three-week study, the findings nevertheless suggest the potential for metabolic problems with long-term treatment.
        </p>
        <p class="headingAnchor" id="H107239049">
         <span class="h2">
          Olanzapine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence for the efficacy of
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         for juvenile mania and mixed mania includes a three-week randomized trial (n = 161) that compared olanzapine (2.5 to 20 mg/day, mean daily dose 9 mg) with placebo [
         <a href="#rid10">
          10
         </a>
         ]. Remission occurred in more patients treated with olanzapine than placebo (35 versus 11 percent). In addition, psychosocial functioning improved more with active drug [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Another important benefit of
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         is that if mania gives way to major depression, it is reasonable to continue olanzapine and add
         <a class="drug drug_pediatric" data-topicid="13315" href="/z/d/drug information/13315.html" rel="external">
          fluoxetine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/15925.html" rel="external">
          "Pediatric bipolar disorder: Overview of choosing treatment", section on 'Major depression'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          Olanzapine
         </a>
         is typically administered once daily at bedtime, and started at a dose of 1 to 5 mg; doses at the lower end of this range are used for children (eg, age 4 to 6 years) and doses at the higher end of the range for adolescents (eg, age 15 to 18 years) [
         <a href="#rid6">
          6
         </a>
         ]. The dose is then titrated up by increments of 1 to 5 mg/day every one to seven days, depending upon response and tolerability. The target dose is 10 mg/day, but efficacious doses range from 2.5 to 20 mg/day [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Weight gain with
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         is problematic:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A three-week randomized (n = 161 manic adolescents) demonstrated that weight gain was greater with
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         than placebo (3.7 versus 0.3 kg) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An eight-week observational study (n = 17 children and adolescents with mania or hypomania) found that mean weight gain exceeded 5 kg [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis of observational and randomized trial data from 179 adolescents with a variety of diagnoses, who were exposed to
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         for at least 24 weeks, found that mean weight gain was &gt;11 kg [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Adjunctive
         <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">
          topiramate
         </a>
         (eg, 25 to 100 mg/day) may partially forestall
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         induced weight gain [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         One randomized trial showed that sedation is more common with
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         than placebo [
         <a href="#rid10">
          10
         </a>
         ]. In addition, olanzapine caused greater increases in systolic blood pressure and pulse, as well as total cholesterol, triglycerides, glucose, hepatic enzymes, prolactin, and uric acid.
        </p>
        <p class="headingAnchor" id="H378722802">
         <span class="h2">
          Paliperidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         An eight-week prospective observational study found that among youth with mania, mixed mania, or hypomania who were treated with
         <a class="drug drug_pediatric" data-topicid="87122" href="/z/d/drug information/87122.html" rel="external">
          paliperidone
         </a>
         (n = 15), remission occurred in seven (47 percent) [
         <a href="#rid15">
          15
         </a>
         ]. The drug was started at 3 mg per day, once per day. In patients 12 years and older who weighed &gt;45 kg, did not respond sufficiently after two weeks, and tolerated the drug, the dose was increased to 6 mg/day. Common side effects included decreased energy, headache, and insomnia; mean weight gain was 1.9 kg. Patients receiving paliperidone should be monitored for side effects that are common with second-generation antipsychotics. (See
         <a class="local">
          'Class-wide side effects'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H107239056">
         <span class="h2">
          Quetiapine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence for the efficacy of
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         in treating pediatric mania and mixed mania includes three randomized trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A three-week trial (n = 277 youth) found that remission occurred in more patients who received
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         400 mg or 600 mg, compared with placebo (45 and 52 versus 23 percent) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A four-week trial compared
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         (400 to 600 mg/day) with divalproex (serum concentration 80 to 120 mcg/mL) in 50 patients, and found that remission occurred in more patients treated with quetiapine than divalproex (60 versus 28 percent) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A six-week trial in 109 youth compared
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         (400 to 600 mg/day) with
         <a class="drug drug_pediatric" data-topicid="12559" href="/z/d/drug information/12559.html" rel="external">
          lithium
         </a>
         (serum concentration 1.0 to 1.2 mEq/L); response occurred more frequently with quetiapine (72 versus 49 percent) [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          Quetiapine
         </a>
         is started at 25 mg at bedtime or 25 mg twice daily. In children (eg, age 4 to 12 years), the dose is usually increased every day by 25 to 50 mg/day, and in adolescents (eg, age 13 to 18 years) by 50 to 100 mg/day [
         <a href="#rid6">
          6
         </a>
         ]. The drug is generally administered in two divided doses; however, once daily dosing may suffice [
         <a href="#rid17">
          17
         </a>
         ]. Although the target dose is 400 to 600 mg/day, clinical experience suggests that some youth respond to 200 to 300 mg/day, and others may require doses &gt;600 mg/day (eg, 800 mg/day).
        </p>
        <p>
         Rapid oral loading of
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         is feasible, generally well tolerated, and may be useful for severely ill patients (eg, inpatients), but is not standard treatment. A randomized trial (n = 25, mean age 15 years) [
         <a href="#rid17">
          17
         </a>
         ] and a retrospective study (n = 75, mean age 10 years) [
         <a href="#rid19">
          19
         </a>
         ] administered quetiapine 100 mg on day one and titrated the drug up to 400 mg/day within four to seven days.
        </p>
        <p>
         Common adverse effects with
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         include dizziness, sedation, tachycardia, and weight gain [
         <a href="#rid6">
          6
         </a>
         ]. In a three-week randomized trial (n = 188) that compared quetiapine (400 mg/day) with placebo, the incidence of dizziness was 19 and 2 percent, sedation was 23 and 4 percent, and tachycardia was 5 and 0 percent; and mean weight gain was 1.7 and 0.4 kg [
         <a href="#rid16">
          16
         </a>
         ]. It may be possible to ameliorate sedation by administering the drug in three divided doses, and/or giving a larger dose at bedtime and a smaller dose during the day.
        </p>
        <p class="headingAnchor" id="H107239063">
         <span class="h2">
          Risperidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several randomized trials indicate that
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         can ameliorate pediatric mania and mixed mania:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A three-week trial compared
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         (target dose either 0.25 to 2.5 mg/day or 3 to 6 mg/day) with placebo in 169 patients [
         <a href="#rid20">
          20
         </a>
         ]. Remission was greater in both groups that received risperidone than placebo (43 and 43 versus 16 percent of patients).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A six-week trial that compared
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         (0.5 to 2.0 mg/day) with divalproex (target serum concentration 80 to 120 mcg/mL) in 65 patients found that remission occurred more often with risperidone (63 versus 33 percent of patients) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An eight-week, open-label trial randomly assigned patients (n = 279) to receive
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         (mean dose 2.6 mg/day),
         <a class="drug drug_pediatric" data-topicid="12559" href="/z/d/drug information/12559.html" rel="external">
          lithium
         </a>
         (mean serum concentration 1.1 mEq/L [1.1 mmol/L]), or divalproex (mean serum concentration 114 mcg/mL) [
         <a href="#rid22">
          22
         </a>
         ]. Response (much or very much improved from baseline) occurred in more patients who received risperidone than lithium or divalproex (69 versus 36 and 24 percent); lithium and divalproex were comparable. Suicidal ideation was present at baseline in 45 percent of the patients treated with risperidone; by week eight, suicidal ideation was observed in 6 percent; comparable reductions occurred with lithium and divalproex. In addition, depressive symptoms during the manic/mixed episode improved more with risperidone than either lithium or divalproex [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients (n = 25) who did not respond to their randomly assigned treatment were included in a second eight-week, open-label randomized trial, along with other patients (n = 64) who were evaluated for the initial trial, but did not participate because they were treated at baseline with one of the three study drugs and were not responding [
         <a href="#rid24">
          24
         </a>
         ]. The 89 patients were randomly assigned to switch to one of the two remaining drugs. Response occurred in more patients who switched to
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         than
         <a class="drug drug_pediatric" data-topicid="12559" href="/z/d/drug information/12559.html" rel="external">
          lithium
         </a>
         or divalproex (48 versus 13 and 17 percent).
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          Risperidone
         </a>
         can be administered orally once daily, or given twice daily to minimize adverse effects [
         <a href="#rid6">
          6
         </a>
         ]. The typical starting dose for children weighing ≤40 kg is 0.25 mg/day, and the dose is increased every one to three days by 0.25 mg/day, depending upon efficacy and tolerability. The maximum generally does not exceed 4 mg/day. For children and adolescents who weigh more than 40 kg, the initial dose is generally 0.5 mg/day, and is increased by 0.25 to 0.5 mg/day every two to three days, with a maximum of 6 mg/day. Although doses up to 6 mg/day have been studied (eg, in youth weighing &gt;50 kg) [
         <a href="#rid22">
          22
         </a>
         ], the efficacy data indicate that many youth respond to lower doses (eg, 0.5 to 2 mg/day).
        </p>
        <p>
         In addition, a case series described three patients who initially responded to oral
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         and were subsequently treated with risperidone long-acting injection [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Common side effects of
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         in children and adolescents include extrapyramidal symptoms (EPS), headache, sedation, and weigh gain [
         <a href="#rid6">
          6
         </a>
         ]. As an example, an eight-week randomized trial (n = 279) found that mean weight gain was greater with risperidone than either
         <a class="drug drug_pediatric" data-topicid="12559" href="/z/d/drug information/12559.html" rel="external">
          lithium
         </a>
         or divalproex (3.3 versus 1.4 or 1.7 kg), and among patients treated with risperidone, sedation from baseline to week 8 increased from 18 to 51 percent [
         <a href="#rid22">
          22
         </a>
         ]. EPS may be reduced by titrating the dose more slowly (eg, increasing the dose every four to five days) and prescribing smaller total daily doses (eg, 1 to 2 mg/day).
        </p>
        <p>
         Although hyperprolactinemia may be greater with
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         than other second-generation antipsychotics, we do not monitor serum prolactin concentrations during treatment with risperidone because side effects attributable to prolactin (eg, irregular menses, galactorrhea, breast enlargement, and decreased bone density) typically do not occur [
         <a href="#rid6">
          6,26
         </a>
         ]. Nevertheless, we suggest obtaining a baseline level prior to starting risperidone; if side effects that may be attributable to hyperprolactinemia emerge, the baseline level can be compared with subsequent levels. The clinical manifestations and evaluation of hyperprolactinemia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6638.html" rel="external">
          "Clinical manifestations and evaluation of hyperprolactinemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H107239070">
         <span class="h2">
          Ziprasidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized trials indicate that
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         is efficacious for youth with mania and mixed mania:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A four-week trial compared
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         with placebo in 237 children and adolescents [
         <a href="#rid27">
          27
         </a>
         ]. The mean modal dose in patients weighing &lt;45 kg was 69 mg/day and for patients ≥45 kg was 119 mg/day. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients treated with ziprasidone than placebo (53 versus 22 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another four-week trial compared
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         with placebo in 171 youth; the mean modal dose in patients weighing &lt;45 kg was 66 mg/day and for patients ≥45 kg was 96 mg/day. Improvement of mania was greater with ziprasidone, and the clinical effect was moderate to large [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          Ziprasidone
         </a>
         is generally started at 20 mg/day at bedtime, and is subsequently administered two times per day with food [
         <a href="#rid27">
          27
         </a>
         ]. The dose is titrated up by 20 mg/day increments approximately every two days, over one to two weeks; increases of 20 mg every day can be used in more severely ill patients. The target dose is 40 to 160 mg/day, depending upon weight (eg, 60 to 80 mg/day for patients &lt;45 kg, and 80 to 160 mg/day for patients ≥45 kg).
        </p>
        <p>
         Common side effects with
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         include akathisia, nausea, and sedation [
         <a href="#rid6">
          6,27
         </a>
         ]. The randomized trial found that sedation occurred in more patients treated with ziprasidone than placebo (33 versus 6 percent), as did nausea (14 versus 7 percent) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         It is prudent to avoid using
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         in patients who are at risk of developing arrhythmias due to electrolyte disturbances, cardiac abnormalities, long QT syndrome, or family history of sudden cardiac death, because of concerns that ziprasidone increases the duration of intracardiac conduction. Nevertheless, in children and adolescents with mania who are otherwise healthy and treated with ziprasidone, the data indicate that the risk of corrected QT (QTc) interval prolongation is modest [
         <a href="#rid6">
          6
         </a>
         ]. As an example, a meta-analysis of randomized trials and prospective observational studies examined increases in QTc interval in youth with various psychiatric diagnoses who were treated with ziprasidone (n = 10 studies and 523 youth; mean dose 63 mg/day) or placebo (n = 19 studies and 962 youth) [
         <a href="#rid29">
          29
         </a>
         ]. The average increase in the QTc was greater with ziprasidone than placebo (9 versus 1 millisecond). However, the incidence of QTc prolongation (defined as QTc &gt;450 milliseconds or increase in QTc &gt;60 milliseconds) was comparable for ziprasidone and placebo. In addition, one of the observational studies found that QTc prolongation occurred in the absence of QTc dispersion and thus concluded that the arrhythmogenic potential of ziprasidone was low [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         There is no established practice for cardiac monitoring of patients receiving
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         . In our practice, we obtain baseline electrocardiograms and repeat them during dose titration (eg, after increasing the dose by 40 or 60 mg/day) [
         <a href="#rid6">
          6,31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3802017622">
         <span class="h2">
          Clozapine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retrospective studies of youth with mania suggest that
         <a class="drug drug_pediatric" data-topicid="12995" href="/z/d/drug information/12995.html" rel="external">
          clozapine
         </a>
         may potentially benefit patients who are refractory to multiple trials of second-generation antipsychotics,
         <a class="drug drug_pediatric" data-topicid="12559" href="/z/d/drug information/12559.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          carbamazepine
         </a>
         , and first-generation antipsychotics [
         <a href="#rid32">
          32-34
         </a>
         ]. However, clozapine is generally reserved for highly refractory patients due to concerns about agranulocytosis, myocarditis, and seizures [
         <a href="#rid6">
          6,31,35
         </a>
         ]. The administration, monitoring, and adverse effects of clozapine are discussed separately in the context of adult schizophrenia. (See
         <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">
          "Schizophrenia in adults: Guidelines for prescribing clozapine"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H761663">
         <span class="h1">
          CLASS-WIDE SIDE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients treated with second-generation antipsychotics should be monitored for side effects that are common in this drug class, including weight gain, extrapyramidal symptoms, and sedation, as well as serious but rare side effects such as the neuroleptic malignant syndrome and tardive dyskinesia [
         <a href="#rid35">
          35
         </a>
         ]. In addition, clinicians should monitor patients for drug-specific adverse effects. (See
         <a class="local">
          'Specific drugs'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H761713">
         <span class="h2">
          Weight gain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children and adolescents who are treated with
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="117924" href="/z/d/drug information/117924.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12995" href="/z/d/drug information/12995.html" rel="external">
          clozapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="87122" href="/z/d/drug information/87122.html" rel="external">
          paliperidone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         are at risk for age inappropriate weight gain and other metabolic effects (eg, increases in total cholesterol and triglycerides) [
         <a href="#rid36">
          36-40
         </a>
         ]. By contrast,
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         does not appear to cause weight gain or dyslipidemia [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Amongst
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         , aripiprazole may cause less weight gain and olanzapine the most. A pooled analysis included 25 studies in which different second-generation antipsychotics were used to treat a variety of psychiatric disorders; the median duration of treatment ranged from 4 to 11 weeks, and the results found that [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight gain was less with
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         than:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          Olanzapine
         </a>
         by 4 kg
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          Quetiapine
         </a>
         by 2 kg
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          Risperidone
         </a>
         by 2 kg
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight gain was greater with
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         than:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          Quetiapine
         </a>
         by 6 kg
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          Risperidone
         </a>
         by 3 kg
        </p>
        <p>
        </p>
        <p>
         In addition, the pooled analysis found that weight gain was comparable with
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         .
        </p>
        <p>
         We suggest that clinicians monitor patients who are prescribed
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="117924" href="/z/d/drug information/117924.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12995" href="/z/d/drug information/12995.html" rel="external">
          clozapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="87122" href="/z/d/drug information/87122.html" rel="external">
          paliperidone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         for metabolic effects  (
         <a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid41">
          41,42
         </a>
         ]. The frequency of monitoring is increased if there are significant changes from baseline. Management of metabolic side effects is discussed separately in the context of adults with schizophrenia. (See
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Metabolic dysregulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H761864">
         <span class="h3">
          Diabetes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple observational studies suggest that second-generation antipsychotics are associated with an increased risk of type 2 diabetes, but the absolute risk seems small. A meta-analysis of six observational studies compared youth exposed to antipsychotics (n &gt;290,000) with unexposed psychiatric controls (n &gt;2,000,000) [
         <a href="#rid43">
          43
         </a>
         ]. The incidence rate of type 2 diabetes was greater in antipsychotic-exposed youth than controls (3.1 versus 1.7 cases per 1000 patient years of follow-up). The risk was higher in males, youth taking
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         , and youth with a longer duration of follow-up. The increased incidence of diabetes observed in youth is consistent with the association between use of antipsychotics in adults and increased rates of weight gain, diabetes, and dyslipidemia. (See
         <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">
          "First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects", section on 'Metabolic syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Metabolic syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H761910">
         <span class="h2">
          Extrapyramidal symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pediatric patients who are treated with second-generation antipsychotics can develop extrapyramidal symptoms such as akathisia, bradykinesia, dystonia, and tremor [
         <a href="#rid6">
          6,26
         </a>
         ]. The Abnormal Involuntary Movement Scale  (
         <a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">
          form 1
         </a>
         ) should be performed at baseline and repeated every 6 to 12 months. In addition, inquiry and examination for extrapyramidal symptoms should occur at each follow-up appointment, particularly during dose titration. Management of extrapyramidal symptoms is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Extrapyramidal symptoms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H761971">
         <span class="h2">
          Sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         All second-generation antipsychotics can cause sedation, which should be monitored at each visit [
         <a href="#rid26">
          26
         </a>
         ]. Adjunctive stimulants for comorbid attention deficit hyperactivity disorder may attenuate sedation caused by atypical antipsychotics. By contrast, other adjunctive drugs for bipolar disorder (eg, divalproex) may exacerbate somnolence.
        </p>
        <p class="headingAnchor" id="H761991">
         <span class="h2">
          Serious but rare effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         In youth treated with atypical antipsychotics, serious but rare side effects include cardiovascular events [
         <a href="#rid44">
          44
         </a>
         ], the neuroleptic malignant syndrome  (
         <a class="graphic graphic_table graphicRef85984" href="/z/d/graphic/85984.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid45">
          45
         </a>
         ] and tardive dyskinesia [
         <a href="#rid46">
          46
         </a>
         ]. These adverse effects are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Cardiovascular events'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H228190228">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">
          "Society guideline links: Bipolar disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H107239077">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Placebo-controlled, randomized trials have demonstrated the efficacy of
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="117924" href="/z/d/drug information/117924.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         for children and adolescents with mania and mixed mania. Other trials have found that risperidone was superior to divalproex or
         <a class="drug drug_pediatric" data-topicid="12559" href="/z/d/drug information/12559.html" rel="external">
          lithium
         </a>
         , and that quetiapine was superior to divalproex or lithium. (See
         <a class="local">
          'Specific drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Target doses and drug specific side effects
         </strong>
         – The target dose and frequent drug specific side effects of second-generation antipsychotics for pediatric mania or mixed mania are as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Aripiprazole
         </strong>
         – 5 to 30 mg/day; akathisia, sedation, nausea, vomiting, and weight gain (see
         <a class="local">
          'Aripiprazole'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asenapine
         </strong>
         – 5 to 20 mg/day; oral hypo/paresthesia, sedation, and weight gain (see
         <a class="local">
          'Asenapine'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Olanzapine
         </strong>
         – 10 mg/day, ranges from 2.5 to 20 mg/day; weight gain, sedation, and increases in systolic blood pressure, pulse, total cholesterol, triglycerides, glucose, hepatic enzymes, prolactin, and uric acid (see
         <a class="local">
          'Olanzapine'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Quetiapine
         </strong>
         – 400 to 600 mg/day, ranges from 200 to 800 mg/day; dizziness, sedation, tachycardia, and weight gain (see
         <a class="local">
          'Quetiapine'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risperidone
         </strong>
         – 1 to 4 mg/day; extrapyramidal symptoms, headache, sedation, and weight gain (see
         <a class="local">
          'Risperidone'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ziprasidone
         </strong>
         – 40 to 160 mg/day; akathisia, nausea, sedation, and increases in the duration of intracardiac conduction (see
         <a class="local">
          'Ziprasidone'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Class-wide adverse effects
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Metabolic effects
         </strong>
         – Children and adolescents who are treated with
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="117924" href="/z/d/drug information/117924.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12995" href="/z/d/drug information/12995.html" rel="external">
          clozapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="87122" href="/z/d/drug information/87122.html" rel="external">
          paliperidone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         are at risk and monitored for metabolic effects  (
         <a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">
          table 1
         </a>
         ). By contrast,
         <a class="drug drug_pediatric" data-topicid="15622" href="/z/d/drug information/15622.html" rel="external">
          ziprasidone
         </a>
         does not appear to cause weight gain or dyslipidemia. (See
         <a class="local">
          'Weight gain'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extrapyramidal symptoms
         </strong>
         – Pediatric patients who are treated with second-generation antipsychotics can develop extrapyramidal symptoms such as akathisia, bradykinesia, dystonia, and tremor, and are monitored with the Abnormal Involuntary Movement Scale  (
         <a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">
          form 1
         </a>
         ). (See
         <a class="local">
          'Extrapyramidal symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sedation
         </strong>
         – All second-generation antipsychotics can cause sedation, which should be monitored at each visit. (See
         <a class="local">
          'Sedation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serious but rare side effects
         </strong>
         – Serious but rare side effects caused by atypical antipsychotics include cardiovascular events, the neuroleptic malignant syndrome  (
         <a class="graphic graphic_table graphicRef85984" href="/z/d/graphic/85984.html" rel="external">
          table 2
         </a>
         ) and tardive dyskinesia. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Cardiovascular events'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Olfson M, Blanco C, Liu SM, et al. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012; 69:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009; 70:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 2009; 70:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling RL, Youngstrom EA, Rowles BM, et al. A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder. J Child Adolesc Psychopharmacol 2017; 27:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling RL, Kauffman R, Sallee FR, et al. An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 2009; 19:431.
          </a>
         </li>
         <li class="breakAll">
          Thomas T, Kuich KW, Findling RL. Bipolar disorders. In: Clinical Manual of Child and Adolescent Psychopharmacology, Second Edition, McVoy M, Findling RL (Eds), American Psychiatric Publishing, Washington, DC 2013. p.227.
         </li>
         <li class="breakAll">
          NICE: National Institute for Health and Care Excellence. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. July 2013. http://www.nice.org.uk/guidance/TA292 (Accessed on December 04, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling RL, Correll CU, Nyilas M, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord 2013; 15:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling RL, Landbloom RL, Szegedi A, et al. Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen BT, Ganocy SJ, Bitter SM, et al. Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine. Compr Psychiatry 2012; 53:1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormack PL. Olanzapine: in adolescents with schizophrenia or bipolar I disorder. CNS Drugs 2010; 24:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wozniak J, Mick E, Waxmonsky J, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009; 19:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kryzhanovskaya LA, Xu W, Millen BA, et al. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 2012; 22:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joshi G, Petty C, Wozniak J, et al. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology (Berl) 2013; 227:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pathak S, Findling RL, Earley WR, et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry 2013; 74:e100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DelBello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patino LR, Klein CC, Strawn JR, et al. A Randomized, Double-Blind, Controlled Trial of Lithium Versus Quetiapine for the Treatment of Acute Mania in Youth with Early Course Bipolar Disorder. J Child Adolesc Psychopharmacol 2021; 31:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheffer RE, Tripathi A, Kirkpatrick FG, Schultz T. Rapid quetiapine loading in youths with bipolar disorder. J Child Adolesc Psychopharmacol 2010; 20:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009; 11:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pavuluri MN, Henry DB, Findling RL, et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord 2010; 12:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 2012; 69:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salpekar JA, Joshi PT, Axelson DA, et al. Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study. J Am Acad Child Adolesc Psychiatry 2015; 54:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walkup JT, Wagner KD, Miller L, et al. Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment. J Am Acad Child Adolesc Psychiatry 2015; 54:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fu-I L, Boarati MA, Stravogiannis A, Wang YP. Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: a case series. J Clin Psychiatry 2009; 70:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69 Suppl 4:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling RL, Cavuş I, Pappadopulos E, et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2013; 23:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findling RL, Atkinson S, Bachinsky M, et al. Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study. J Child Adolesc Psychopharmacol 2022; 32:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen KG, Juul K, Fink-Jensen A, et al. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 2015; 54:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correll CU, Lops JD, Figen V, et al. QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry 2011; 72:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas T, Stansifer L, Findling RL. Psychopharmacology of pediatric bipolar disorders in children and adolescents. Pediatr Clin North Am 2011; 58:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002; 12:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowatch RA, Suppes T, Gilfillan SK, et al. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series. J Child Adolesc Psychopharmacol 1995; 5:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: recent progress. CNS Drugs 2010; 24:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varley CK, McClellan J. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. JAMA 2009; 302:1811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seida JC, Schouten JR, Boylan K, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012; 129:e771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arango C, Giráldez M, Merchán-Naranjo J, et al. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry 2014; 53:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McClellan J, Kowatch R, Findling RL, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:107.
          </a>
         </li>
         <li class="breakAll">
          NICE National Institute for Health and Care Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. September 2014. http://www.nice.org.uk/guidance/CG185 (Accessed on November 18, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galling B, Roldán A, Nielsen RE, et al. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry 2016; 73:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shain BN, COMMITTEE ON ADOLESCENCE. Collaborative role of the pediatrician in the diagnosis and management of bipolar disorder in adolescents. Pediatrics 2012; 130:e1725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008; 69:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007; 17:647.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 98719 Version 6.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22868273" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National trends in the office-based treatment of children, adolescents, and adults with antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19906348" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19389329" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28759262" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19702495" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19702495" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19702495" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23437959" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26598478" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17898346" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Olanzapine versus placebo in the treatment of adolescents with bipolar mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22520085" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20369908" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Olanzapine: in adolescents with schizophrenia or bipolar I disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19877978" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22372514" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23397049" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23419231" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16540815" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34520250" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A Randomized, Double-Blind, Controlled Trial of Lithium Versus Quetiapine for the Treatment of Acute Mania in Youth with Early Course Bipolar Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20973715" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Rapid quetiapine loading in youths with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19839994" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20868458" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22213771" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26598475" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Depression and Suicidality Outcomes in the Treatment of Early Age Mania Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26598476" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Treatment of Early-Age Mania: Outcomes for Partial and Nonresponders to Initial Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19403102" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18533766" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24111980" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35394365" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25524787" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21457682" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : QT interval duration and dispersion in children and adolescents treated with ziprasidone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21281855" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Psychopharmacology of pediatric bipolar disorders in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12188978" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clozapine in adolescent inpatients with acute mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15725966" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Treatment guidelines for children and adolescents with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20441242" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pharmacotherapy of bipolar disorder in children and adolescents: recent progress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19861668" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19861677" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22351885" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Antipsychotics for children and young adults: a comparative effectiveness review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25440308" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26388529" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17195735" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17195735" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26792761" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23184107" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Collaborative role of the pediatrician in the diagnosis and management of bipolar disorder in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18572981" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17979584" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
